NCT00312013

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 503 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).

Conditions

• Thrombosis, Venous

Interventions

Type	Name	Description
DRUG	Nadroparin	Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.

Timeline

• Start date: 2006-05-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2006-04-07
• Last updated: 2017-03-23

Locations

95 sites across 11 countries: Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Russia, Slovenia